Background: Ovarian cancer (OC) is a severe malignant tumor with a significant threat to women's health, characterized by a high mortality rate and poor prognosis despite conventional treatments such as cytoreductive surgery and platinum-based chemotherapy. Cuproptosis, a novel form of cell death triggered by copper ion accumulation, has shown potential in cancer therapy, particularly through the involvement of CuLncs. This study aims to identify risk signatures associated with CuLncs in OC, construct a prognostic model, and explore potential therapeutic drugs and the impact of CuLncs on OC cell behavior.
Methods: We analyzed ovarian cancer data (TCGA-OV) from the TCGA database, including transcriptomic and clinical data from 376 patients. Using Pearson correlation and LASSO regression, we identified 8 prognostic CuLncs to construct a risk signature model. Patients were categorized into high- and low-risk groups based on their risk scores. We performed survival analysis, model validation, drug sensitivity analysis, and experiments to assess the model's performance and the functional impact of key CuLncs on OC cell proliferation, invasion, and migration.
Results: The prognostic model demonstrated significant predictive power, with an area under the curve (AUC) of 0.702 for 1-year, 0.640 for 3-year, and 0.618 for 5-year survival, outperforming clinical pathological features such as stage and grade. High-risk OC patients exhibited higher Tumor Immune Dysfunction and Exclusion (TIDE) scores, indicating stronger immune evasion ability. Drugs such as JQ12, PD-0325901, and sorafenib showed reduced IC50 values in the high-risk group, suggesting potential therapeutic benefits. experiments revealed that knockdown of LINC01956, a key CuLnc in the risk signature, significantly inhibited the proliferation, invasion, and migration of OC cells (P<0.05).
Conclusion: Our study identified a prognostic risk model based on CuLncs and explored their potential as therapeutic targets in OC. The findings highlight the importance of CuLncs in OC prognosis and immune response, providing new insights for future research and clinical applications.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893572 | PMC |
http://dx.doi.org/10.3389/fimmu.2025.1555782 | DOI Listing |
Sci Transl Med
March 2025
Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China.
The benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer remains controversial, hindering the development of rational combination therapies based on hyperthermia (HT). This study reports the preliminary results of the neoadjuvant HIPEC (NHIPEC) trial (ChiCTR2000038173), demonstrating enhanced tumor response in high-grade serous ovarian cancer with NHIPEC. Through single-cell RNA sequencing analysis, we identified both homogeneous and heterogeneous cellular responses to HT within the tumor and microenvironment.
View Article and Find Full Text PDFCancer
March 2025
Department of Oncology, Karmanos Cancer Institute at Wayne State University, Detroit, Michigan, USA.
Background: Prior studies of participants with breast and other obesity-associated cancers in the Women's Health Initiative (WHI) showed worse mortality and cardiovascular disease (CVD) outcomes for individuals with a higher number of cardiometabolic risk factors at study entry. The purpose of this analysis is to compare the relationship between cardiometabolic abnormalities and mortality among women with and without cancer in the WHI.
Methods: Women with one of five early-stage obesity-associated cancers (breast, colorectal, endometrial, ovarian, and non-Hodgkin lymphoma) and controls without any new or prior history of cancer were selected from the WHI-Life and Longevity after Cancer ancillary study.
Reprod Sci
March 2025
Departments of Obstetrics and Gynecology and Biochemistry and Molecular Biology, the C.S. Mott Center for Human Growth and Development, Wayne State University School of Medicine, Detroit, MI, 48201, USA.
Glyphosate-based herbicides (GBHs) are the most widely used herbicides in the United States, accounting for 19% of estimated global use. Although the Environmental Protection Agency (EPA) has reaffirmed that the active ingredient glyphosate (GLY) is safe for humans, recent studies on exposure have suggested association with cancer, metabolic disorders, endocrine disruption and infertility, Alzheimer's and Parkinson's disease, and psychological disorders. Current literature on the effects of GLY exposure on reproductive function suggests potential clinical implications on women's reproductive health, including polycystic ovarian syndrome (PCOS), endometriosis, infertility, and adverse pregnancy outcomes.
View Article and Find Full Text PDFEur J Cancer Prev
March 2025
Department of Oncology and Hemato-Oncology, University of Milan.
Endometriosis is one of the most common gynecological benign disease. Epidemiological evidence suggests a potential association between endometriosis and cancer risk. Accumulating evidence highlighted the risk of ovarian cancer, particularly endometrioid and clear cell subtypes.
View Article and Find Full Text PDFCells
March 2025
Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Ovarian cancer survival depends strongly on the time of diagnosis. Detection at stage 1 must be the goal of liquid biopsies for ovarian cancer detection. We report the development and validation of graphene-based optical nanobiosensors (G-NBSs) that quantify the activities of a panel of proteases, which were selected to provide a crowd response that is specific for ovarian cancer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!